Addressing the Symptom Burden of Moderate-to-Severe Atopic Dermatitis with Targeted Therapies: Clinical Pearls for Primary Care
This program aims to help clinicians better identify clinical presentation features of atopic dermatitis (AD) warranting a timely and accurate differential diagnosis; recognize patients for whom biologic therapies should be considered as part of treatment plans for the management of moderate-to-severe AD, and coordinate with specialists to provide patient-specific, long-term care for moderate-to-severe AD.
RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026
Approaches to Achieving Treatment Objectives for Patients with MODERATE TO SEVERE ASTHMA
Learn More & View Event »
Bridging the Gap Between Dermatology, Primary Care, and Pediatric Care for Patients With Moderate-to-Severe Atopic Dermatitis
This innovative online enduring activity is designed to enhance clinicians’ understanding and management of atopic dermatitis (AD). It equips healthcare professionals with the knowledge to recognize the clinical characteristics of AD, highlighting key differences between adults and pediatric presentations. The program also explores the therapeutic benefits of biologics for patients with moderate-to-severe AD. Additionally, it promotes a multidisciplinary team (MDT) approach to improve collaboration across specialties, emphasizing timely dermatology referrals for optimal patient care.
RELEASED DATE: September 30, 2025
EXPIRATION DATE: September 30, 2026
Can Biologics Targeting Type 2 Inflammatory Mediators Play a Role in the Management of Patients with COPD?
Learn More & View Event »
Data Talk: Decoding Biologics for the Diagnosis and Treatment of Bullous Pemphigoid
The goal of this program is to enhance learners’ familiarity with the roles of key drivers of bullous pemphigoid (BP) that inform diagnosis and potential treatment targets. Learners will gain the ability to achieve a timely and accurate diagnosis of BP, including knowing how and when to refer to specialists. They will also have increased awareness of the need for improved treatment options for BP and awareness of the clinical profiles of novel treatment options for BP targeting different immune pathways.
RELEASED DATE: February 13, 2025
EXPIRATION DATE: March 06, 2026
Individualizing Patient Care in COPD: Treating the Underlying Endophenotype and Use of Multidisciplinary Teams
This enduring activity is designed to provide healthcare professionals with a comprehensive understanding of the role of type 2 inflammation in the pathophysiology of Chronic Obstructive Pulmonary Disease (COPD) and its implications for treatment strategies. The latest developments in the treatment of COPD using approved and investigational biologics will be discussed featuring evidence-based and real-world experiences. Participants will gain valuable insights into improving the management of COPD using a multidisciplinary approach.
RELEASED DATE: May 17, 2025
EXPIRATION DATE: May 17, 2026
Management of Chronic Obstructive Pulmonary Disease Using Evidence-Based Approaches
Learn More & View Event »
Moderate-to-Severe Asthma: Targeting Underlying Inflammatory Processes to Improve Patient Outcomes
This enduring program consists of presentations from expert faculty and simulation challenge animations that will explain immune dysfunction and the pathogenesis of moderate-to-severe asthma, currently available and emerging targeted therapies used for asthma, and the usefulness and application of guidelines and biomarkers to guide treatment selection for this disease.
Navigating the Complexities of Moderate-to-Severe Asthma from Diagnosis to Treatment Selection in Veteran Patients
Veterans face a unique and heightened burden from moderate-to-severe asthma, experiencing worsened morbidity and mortality due to the condition. This grand rounds enduring is designed to equip healthcare professionals in the VA setting with practical, evidence-based strategies to improve care for veteran patients with moderate-to-severe asthma. Through interactive, case-based learning, participants will enhance their understanding of type 2 inflammation, gain proficiency in the use of biologic therapies, and learn to individualize treatment plans to their veteran patients’ needs, all with the goal of improving outcomes for veteran patients with moderate-to-severe asthma.
RELEASED DATE: November 21, 2025
EXPIRATION DATE: November 21, 2026
Personalized Treatment to Improve Breathing and Reduce Inflammation in Patients with Moderate-to-Severe Asthma
This enduring activity is designed to enhance healthcare professionals’ understanding of the role of type 2 inflammation in asthma’s complex pathology and its impact on disease progression. Participants will explore evidence-based approaches for incorporating biologic therapies into individualized treatment plans and learn strategies for selecting the most appropriate biologic therapy based on patient-specific needs, preferences, and goals to optimize outcomes in moderate-to-severe asthma management. The program will also review GINA recommendations and when to incorporate biologic therapy.
RELEASED DATE: October 30, 2025
EXPIRATION DATE: October 30, 2026
